3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Glioblastoma
3
Gliosarcoma
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
trametinib
2
dabrafenib
2
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
thymoglobulin
1
temsirolimus
1
sapanisertib
1
ropidoxuridine
1
romidepsin
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
entrectinib
1
defactinib
1
copanlisib
1
cobimetinib
1
ceritinib
1
cc-486
1
capmatinib
1
capivasertib
1
bintrafusp alfa protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
capmatinib
×
CNS
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled